[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Jung DI, Park C, Kang BT, Kim JW, Kim HJ, Lim CY, Jeong SW, Park HM: Acquired cervical syringomyelia secondary to a brainstem meningioma in a maltese dog. J Vet Med Sci; 2006 Nov;68(11):1235-8
SciCrunch. OMIA - Online Mendelian Inheritance in Animals: Data: Gene Expression .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired cervical syringomyelia secondary to a brainstem meningioma in a maltese dog.
  • The lateral, third and fourth ventricles and central canal of the cervical spinal cord were enlarged.
  • The clinical signs were controlled well by lomustine and the dog survived for 8 months after the initial diagnosis.
  • The mass was diagnosed as a meningioma based on histopathological findings.
  • This report describes the clinical findings and imaging characteristics of an acquired syringomyelia resulting from a brainstem meningioma.

  • MedlinePlus Health Information. consumer health - Syringomyelia.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17146188.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7BRF0Z81KG / Lomustine
  •  go-up   go-down


2. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature.
  • INTRODUCTION: One in every thousand intracranial meningiomas metastatize extracranially.
  • To our knowledge, this is the first description of a total en bloc spondylectomy through a posterior approach for the treatment of an intraosseous metastatic meningioma to the eleventh dorsal vertebra.
  • CASE REPORT: In March 1996, a 37 year-old male underwent surgical resection for a left occipital intraventricular benign meningioma (WHO I).
  • By the end on 2003 he developed progressively invalidating dorsolumbar pain.
  • The pathological specimen was identified as adenocarcinoma and he initiated chemotherapy.
  • Advice from a second pathologist was seeked, who suggested the diagnosis of intraosseous meningioma.
  • In May 2004 the patient was admitted to our department and a new transpedicular biopsy confirmed the diagnosis.
  • In June 2004 he underwent T11 total en bloc spondylectomy (Tomita's procedure), fusion with bone and calcium substitute-filled stackable carbon-fiber cages, and T9 to L1 transpedicular screw fixation.
  • Definite pathology: benign meningioma (WHO I).
  • DISCUSSION: Distant metastases from intracranial meningiomas are rare entities, arising from benign lesions in, at least, 60% of cases.
  • Enam et al proposed a specific pathological score to differentiate benign, atypic and malignant meningiomas.
  • Such score correlates with the chance of metastatizing: more than 40% in malignant meningiomas compared to 3.8% of brain tumors overall.
  • We believe this case represents a paradigmatic indication of this technique because it respects the concepts of radical resection and spinal stability, and offers an opportunity for the curation of the disease.
  • [MeSH-major] Meningioma / pathology. Orthopedic Procedures / methods. Spinal Neoplasms / secondary. Spinal Neoplasms / surgery. Thoracic Vertebrae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


3. Taylor AJ, Little MP, Winter DL, Sugden E, Ellison DW, Stiller CA, Stovall M, Frobisher C, Lancashire ER, Reulen RC, Hawkins MM: Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol; 2010 Dec 20;28(36):5287-93
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: CNS tumors are the most common second primary neoplasm (SPN) observed after childhood cancer in Britain, but the relationship of risk to doses of previous radiotherapy and chemotherapy is uncertain.
  • METHODS: The British Childhood Cancer Survivor Study is a national, population-based, cohort study of 17,980 individuals surviving at least 5 years after diagnosis of childhood cancer.
  • RESULTS: There were 137 meningiomas, 73 gliomas, and 37 other CNS neoplasms included in the analysis.
  • The risk of meningioma increased strongly, linearly, and independently with each of dose of radiation to meningeal tissue and dose of intrathecal methotrexate.
  • Those whose meningeal tissue received 0.01 to 9.99, 10.00 to 19.99, 20.00 to 29.99, 30.00 to 39.99 and≥40 Gy had risks that were two-fold, eight-fold, 52-fold, 568-fold, and 479-fold, respectively, the risks experienced by those whose meningeal tissue was unexposed.
  • The risk of meningioma among individuals receiving 1 to 39,40 to 69, and at least 70 mg/m2 of intrathecal methotrexate was 15-fold, 11-fold, and 36-fold, respectively, the risk experienced by those unexposed.
  • The risk of glioma/primitive neuroectodermal tumors increased linearly with dose of radiation, and those who had CNS tissue exposed to at least 40 Gy experienced a risk four-fold that experienced by those who had CNS tissue unexposed.
  • CONCLUSION: The largest-ever study, to our knowledge, of CNS tumors in survivors of childhood cancer indicates that the risk of meningioma increases rapidly with increased dose of radiation to meningeal tissue and with increased dose of intrathecal methotrexate.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21079138.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / ZIA CP010131-18; United Kingdom / Cancer Research UK / / ; United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS533866; NLM/ PMC4809645
  •  go-up   go-down


Advertisement
4. Pamuk ON, Harmandar F: A case of cervical spine meningioma following etanercept use in a patient with RA. Nat Rev Rheumatol; 2009 Aug;5(8):457-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of cervical spine meningioma following etanercept use in a patient with RA.
  • BACKGROUND: A 70-year-old female with active rheumatoid arthritis (RA) was administered etanercept to treat active disease that persisted despite therapy with conventional DMARDs.
  • After 18 months of etanercept therapy, her RA symptoms had improved; however, she developed quadriparesis.
  • DIAGNOSIS: The patient underwent neurosurgery to resect a 1 x 2 cm mass in the cervical spine at C6-C7.
  • Histopathologic examination of the excised mass revealed it to be a meningioma.
  • MANAGEMENT: Etanercept was discontinued because of a possible association between the drug and development of meningioma; however, shortly afterwards the patient experienced a flare of RA symptoms.
  • To our knowledge, this is the first report in the literature of meningioma developing following use of tumor necrosis factor inhibitor therapy, and the first to suggest a cause-effect relationship.
  • [MeSH-major] Antirheumatic Agents / adverse effects. Arthritis, Rheumatoid / drug therapy. Immunoglobulin G / adverse effects. Meningioma / chemically induced. Spinal Cord Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • Hazardous Substances Data Bank. Etanercept .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648944.001).
  • [ISSN] 1759-4804
  • [Journal-full-title] Nature reviews. Rheumatology
  • [ISO-abbreviation] Nat Rev Rheumatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; OP401G7OJC / Etanercept
  •  go-up   go-down


5. Hemminki K, Lenner P, Sundquist J, Bermejo JL: Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis. J Clin Oncol; 2008 Apr 10;26(11):1850-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis.
  • PURPOSE: Quantitative data on subsequent cancers after primary cancers provide information on treatment-related risks on second cancers, with implications for therapeutic adverse effects and human susceptibility in general.
  • We focus on survivors of non-Hodgkin's lymphoma (NHL) because the disease is diagnosed at a wide range of ages and treated uniformly primarily with chemotherapy.
  • Among the 25 most common solid tumors, the SIRs were increased for all but nine sites; the highest SIR (40.8) was observed for spinal meningioma.
  • In the most common patient groups, the SIRs for solid tumors increased up to 30 years after NHL diagnosis.
  • Because of the high incidence of solid tumors in these age groups, they contributed the largest numbers of therapy-related cases.
  • CONCLUSION: These data indicate that age at treatment determines both the magnitude of the initial relative risk and the time-dependent modulation of the response.
  • Therapy-related damage persists at least 30 years and its toll of solid tumors is largest 21 to 30 years after diagnosis.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Age of Onset. Aged. Aging. Child. Child, Preschool. Comorbidity. Female. Follow-Up Studies. Humans. Incidence. Infant. Infant, Newborn. Male. Meningioma / diagnosis. Meningioma / epidemiology. Middle Aged. Registries. Risk Assessment. Sex Distribution. Spinal Neoplasms / diagnosis. Spinal Neoplasms / epidemiology. Sweden / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347006.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


6. Epstein NE, Drexler S, Schneider J: Clear cell meningioma of the cauda equina in an adult: case report and literature review. J Spinal Disord Tech; 2005 Dec;18(6):539-43
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell meningioma of the cauda equina in an adult: case report and literature review.
  • In the pediatric population, clear cell meningiomas are more frequently intracranial than intraspinal in location.
  • Tumors recur in up to 40% of cases within 15 postoperative months and are often managed with repeated resection with or without radiation therapy.
  • The management strategy for adults with clear cell meningiomas involving the lumbar spinal canal (cauda equina) is less clearly defined.
  • An enhanced magnetic resonance (MR) scan revealed a homogeneously enhancing intradural lesion filling the spinal canal at the L3-L4 level.
  • Frozen-section diagnosis confirmed clear cell tumor.
  • Differential diagnoses included meningioma versus renal cell carcinoma.
  • Negative postoperative chest, abdominal, and pelvic computed tomography studies ruled out tumor of renal cell origin.
  • Consultations with multiple oncologists and radiation therapists recommended neither radiation nor chemotherapy following this initial surgery.
  • The high recurrence rate for clear cell meningiomas in children requires repeated tumor resection with or without secondary radiation therapy.
  • Following gross total resection of lumbar tumors in adults, reserving radiation therapy for secondary recurrences provides optimal management.
  • [MeSH-major] Cauda Equina / pathology. Cauda Equina / surgery. Meningioma / diagnosis. Meningioma / surgery. Peripheral Nervous System Neoplasms / diagnosis. Peripheral Nervous System Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Paresis / diagnosis. Paresis / etiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16306847.001).
  • [ISSN] 1536-0652
  • [Journal-full-title] Journal of spinal disorders & techniques
  • [ISO-abbreviation] J Spinal Disord Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


7. Mizutani J, Fukuoka M, Tsubouchi S, Otsuka T, Tono Y, Shimizu S, Matsui N: A rare case of lumbosacral meningioma: nondural attachment and possible enlargement by orally administered sex steroid. Spine (Phila Pa 1976); 2002 Aug 15;27(16):E377-81
Hazardous Substances Data Bank. MESTRANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of lumbosacral meningioma: nondural attachment and possible enlargement by orally administered sex steroid.
  • OBJECTIVES: To present a very rare case of orally ingested sex hormone pills inducing nondurally attached meningioma in the lumbosacral region.
  • SUMMARY OF BACKGROUND DATA: Meningiomas are known to enlarge in response to female sex hormones.
  • At this writing, few cases of nondurally based intradural meningioma have been reported.
  • Moreover, meningiomas in the lumbosacral region are very rare.
  • Spinal meningiomas predominantly arise in the fourth to sixth decades of life and are more common in women.
  • She had undergone oral sex steroid therapy for long-term oligomenorrhea.
  • However, the pathologic diagnosis was meningioma.
  • Nondural attachment intradural meningiomas are quite uncommon.
  • Care must be taken in the management of lumbosacral intradural tumors because tumors resembling neurilemmoma may in fact represent meningioma, some subtypes of which possess a high rate of recurrence.
  • [MeSH-major] Dura Mater / pathology. Gonadal Steroid Hormones / adverse effects. Meningioma / chemically induced. Meningioma / diagnosis. Spinal Cord Neoplasms / chemically induced. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Administration, Oral. Adult. Cauda Equina / pathology. Cauda Equina / radiography. Cauda Equina / surgery. Chlormadinone Acetate / administration & dosage. Chlormadinone Acetate / adverse effects. Diagnosis, Differential. Female. Humans. Hypesthesia / etiology. Low Back Pain / etiology. Lumbosacral Region. Magnetic Resonance Imaging. Mestranol / administration & dosage. Mestranol / adverse effects. Myelography. Neurilemmoma / diagnosis. Oligomenorrhea / drug therapy. Spine / pathology. Spine / radiography. Spine / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHLORMADINONE ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12195080.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones; 0SY050L61N / Chlormadinone Acetate; B2V233XGE7 / Mestranol
  •  go-up   go-down


8. Raina GB, Piedimonte F, Micheli F: Posterior spinal cord stimulation in a case of painful legs and moving toes. Stereotact Funct Neurosurg; 2007;85(6):307-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posterior spinal cord stimulation in a case of painful legs and moving toes.
  • Symptoms developed initially when walking and progressively became bilateral, appeared at rest and involuntary movements of the toes became evident.
  • A diagnosis of painful legs and moving toes was made.
  • As several drug therapies proved unsuccessful, a therapeutic test with a tetrapolar epidural lead to stimulate the spinal cord dorsal tracts was performed.
  • Due to the marked improvement the device and generator were implanted and she has responded satisfactorily to this therapy for the past 13 months.
  • [MeSH-major] Electric Stimulation Therapy / methods. Movement Disorders / therapy. Pain Management. Spinal Cord / physiology
  • [MeSH-minor] Electromyography. Female. Humans. Magnetic Resonance Imaging. Meningeal Neoplasms / complications. Meningeal Neoplasms / pathology. Meningioma / complications. Meningioma / pathology. Middle Aged. Neural Conduction. Pain / etiology. Pain / pathology. Posterior Horn Cells / physiology. Toes

  • MedlinePlus Health Information. consumer health - Movement Disorders.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 17709986.001).
  • [ISSN] 1423-0372
  • [Journal-full-title] Stereotactic and functional neurosurgery
  • [ISO-abbreviation] Stereotact Funct Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


9. Martin AJ, Hammond CJ, Dobbs HJ, Al-Sarraj S, Thomas NW: Spinal meningioma after treatment for Hodgkin disease. Case report. J Neurosurg; 2001 Oct;95(2 Suppl):232-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal meningioma after treatment for Hodgkin disease. Case report.
  • Long-term survivors of Hodgkin disease may develop second primary tumors caused by the mutagenic effects of radio- and chemotherapy.
  • The authors describe the case of a 35-year-old woman who presented with an unusual meningioma of the cervical spine 9 years after undergoing combined-modality treatment for Hodgkin disease.
  • To the authors' knowledge, this is the first report of spinal meningioma as a complication of such therapy.
  • Whereas radiation-induced intracranial meningiomas are well described in the literature, treatment-induced meningiomas of the spine have not been widely recognized.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hodgkin Disease / therapy. Meningioma / etiology. Neoplasms, Second Primary. Spinal Neoplasms / etiology
  • [MeSH-minor] Adult. Combined Modality Therapy / adverse effects. Female. Humans. Radiotherapy / adverse effects

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Meningioma, spinal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11599842.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Riffaud L, Bernard M, Lesimple T, Morandi X: Radiation-induced spinal cord glioma subsequent to treatment of Hodgkin's disease: case report and review. J Neurooncol; 2006 Jan;76(2):207-11
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced spinal cord glioma subsequent to treatment of Hodgkin's disease: case report and review.
  • Radiation-induced neoplasms of the central nervous system generally present as meningioma or sarcoma.
  • Spinal cord glioma after radiation therapy is rare and half of the cases documented occurred after treatment of Hodgkin's disease.A 39-year-old male presented with a 1-month history of gradually worsening neck ache and paraparesis.
  • The patient had been treated for stage IB Hodgkin's disease 9 years previously with combined therapy: MOPP-ABV and a 40-Gray mediastinal radiotherapy from T1 to T10.
  • Despite chemotherapy and additional radiotherapy, the patient's neurological status worsened and he died 11 months after initial presentation.
  • We suggest a strategy aimed solely at obtaining a tissue diagnosis to differentiate myelitis from tumor, and, in the event of tumor, confirming the strong likelihood of a high histopathological grade.
  • The very limited survival associated with these tumors regardless of therapy advocates palliative therapies without attempting complete resection.
  • [MeSH-major] Glioma / etiology. Hodgkin Disease / complications. Hodgkin Disease / radiotherapy. Neoplasms, Radiation-Induced / pathology. Spinal Cord Neoplasms / etiology
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Spinal Cord / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1976 Nov;38(5):1939-40 [991108.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):19-26 [14700605.001]
  • [Cites] Lancet. 1975 Apr 26;1(7913):947-9 [48122.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1974 Oct;37(10 ):1177-80 [4443812.001]
  • [Cites] Cancer. 1980 Apr 15;45(8):2051-5 [7370950.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):590-5 [7674006.001]
  • [Cites] Cancer. 1986 Aug 15;58(4):886-94 [2424587.001]
  • [Cites] Neurosurgery. 1986 Jun;18(6):721-4 [3736799.001]
  • [Cites] J Neurosurg. 2001 Oct;95(2 Suppl):232-5 [11599842.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 2:101-6 [7515642.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] Pediatr Neurosurg. 1996 Oct;25(4):214-9 [9293548.001]
  • [Cites] N Engl J Med. 1972 Nov 30;287(22):1119-22 [5082192.001]
  • [Cites] Neurosurgery. 1991 Oct;29(4):606-8 [1658678.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Neurosurgery. 1985 Sep;17(3):436-45 [2995867.001]
  • [Cites] J Neurosurg. 1980 Jun;52(6):838-41 [7381543.001]
  • [Cites] Neuroradiology. 1990;32(4):331-3 [2234396.001]
  • [Cites] J Natl Cancer Inst. 1984 Feb;72(2):233-41 [6420598.001]
  • [Cites] Lancet. 1974 Feb 23;1(7852):277-9 [4130470.001]
  • [Cites] Surg Neurol. 1976 Apr;5(4):215-9 [817405.001]
  • [Cites] Cancer. 1976 Feb;37(2 Suppl):1024-32 [766952.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1989-96 [12200357.001]
  • [Cites] Ann Oncol. 1992 Sep;3 Suppl 4:117-28 [1450072.001]
  • [Cites] Med Pediatr Oncol. 1987;15(2):89-95 [3295502.001]
  • [Cites] J Neurosurg. 1989 Jan;70(1):50-4 [2909688.001]
  • (PMID = 16158216.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Lacoste-Collin L, Roux FE, Gomez-Brouchet A, Despeyroux ML, Uro-Coste E, Coindre JM, Delisle MB: Inflammatory myofibroblastic tumor: a spinal case with aggressive clinical course and ALK overexpression. Case report. J Neurosurg; 2003 Mar;98(2 Suppl):218-21
Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor: a spinal case with aggressive clinical course and ALK overexpression. Case report.
  • The authors report on a case of spinal inflammatory myofibroblastic tumor (IMT) in a 22-year-oldwoman.
  • Neuroradiological features of this intradural extramedullary mass were suggestive of a meningioma or neurinoma.
  • This led to the diagnosis of IMT.
  • The patient's postoperative course was complicated by a multifocal local recurrence requiring a second surgery, which was followed by radio- and chemotherapy.
  • The occurrence of IMT in the spinal cord has rarely been reported.
  • [MeSH-major] Fibroblasts / pathology. Muscle, Smooth / pathology. Protein-Tyrosine Kinases / metabolism. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / enzymology
  • [MeSH-minor] Adult. Female. Humans. Inflammation / diagnosis. Inflammation / pathology. Inflammation / physiopathology. Magnetic Resonance Imaging. Receptor Protein-Tyrosine Kinases

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12650409.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


12. Giordano F, Savarino A, Pagni CA: Spinal meningioma during hydroxyurea therapy. A paradoxycal case report. Neurol Sci; 2002 Sep;23(3):127-9
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal meningioma during hydroxyurea therapy. A paradoxycal case report.
  • We report the case of a 65-year-old woman who developed symptoms of spinal cord compression due to a spinal meningioma after 10 years of treatment with hydroxyurea (1000 mg/day) for essential thrombocytemia.
  • This case provides a paradigm for the occurrence of symptomatic meningioma in course of HU therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hydroxyurea / therapeutic use. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy. Spinal Cord / drug effects. Thrombocythemia, Essential / complications. Thrombocythemia, Essential / drug therapy
  • [MeSH-minor] Aged. Cervical Vertebrae. Female. Humans. Laminectomy. Magnetic Resonance Imaging. Treatment Failure. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Meningioma, spinal.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12391498.001).
  • [ISSN] 1590-1874
  • [Journal-full-title] Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  • [ISO-abbreviation] Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


13. Cramer P, Thomale UW, Okuducu AF, Lemke AJ, Stockhammer F, Woiciechowsky C: An atypical spinal meningioma with CSF metastasis: fatal progression despite aggressive treatment. Case report. J Neurosurg Spine; 2005 Aug;3(2):153-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An atypical spinal meningioma with CSF metastasis: fatal progression despite aggressive treatment. Case report.
  • The authors report the case of a 23-year-old man who presented with a C1-3 spinal mass.
  • Following intraspinal decompression the tumor was histologically classified as an atypical meningioma (World Health Organization grade II).
  • Two further surgical interventions resulted in almost total removal of the meningioma.
  • Despite additional hydroxyurea-based chemotherapy, the patient presented 4 months later with a hemiparesis and a massive recurrence of the tumor mass involving the posterior fossa and the upper thoracic spine.
  • The authors discuss more aggressive therapeutic options in addition to surgery in patients with metastatic atypical meningiomas.
  • The results in the reported case indicate that meningiomas associated with cerebrospinal fluid metastasis may represent a higher grade of malignancy.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Cervical Vertebrae. Decompression, Surgical. Disease Progression. Fatal Outcome. Humans. Hydroxyurea / therapeutic use. Joint Instability / etiology. Magnetic Resonance Imaging. Male. Myelography. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neurosurgical Procedures / adverse effects. Radiotherapy, Adjuvant. Reoperation. Spinal Diseases / etiology

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Meningioma, spinal.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16370305.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


14. Zarovnaya EL, Pallatroni HF, Hug EB, Ball PA, Cromwell LD, Pipas JM, Fadul CE, Meyer LP, Park JP, Biegel JA, Perry A, Rhodes CH: Atypical teratoid/rhabdoid tumor of the spine in an adult: case report and review of the literature. J Neurooncol; 2007 Aug;84(1):49-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There have been only 17 cases of AT/RT in adults reported in the medical literature and the rarity of this tumor makes the diagnosis in adults difficult.
  • We describe a case of an AT/RT of the spinal cord in an adult.
  • An MRI demonstrated a mass lesion in the dorsal spinal cord extending from C4 to C6.
  • In consultation with senior pathologists at other institutions, the lesion was initially diagnosed as a rhabdoid meningioma.
  • Subsequently, immunohistochemical studies revealed the absence of INI1 gene expression in the malignant cells, supporting the diagnosis of AT/RT.
  • Despite aggressive surgical resection, adjuvant chemotherapy and radiation therapy, the patient succumbed to the disease two and a half years after her initial presentation.
  • To our knowledge, this is the first case of a spinal atypical teratoid/rhabdoid tumor in an adult fully documented with molecular, immunohistochemical, cytogenetic and autopsy findings.
  • [MeSH-major] Chromosomal Proteins, Non-Histone / genetics. Chromosomes, Human, Pair 22 / genetics. DNA-Binding Proteins / genetics. Neoplasm Recurrence, Local / pathology. Rhabdoid Tumor / pathology. Spinal Cord Neoplasms / pathology. Teratoma / pathology. Transcription Factors / genetics
  • [MeSH-minor] Adult. Cervical Vertebrae. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Monosomy / diagnosis. Monosomy / genetics. SMARCB1 Protein

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2001 Mar;52(1):49-56 [11451202.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):121-6 [12622450.001]
  • [Cites] Nature. 1998 Jul 9;394(6689):203-6 [9671307.001]
  • [Cites] Genes Dev. 2005 Mar 15;19(6):665-70 [15769941.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):951-8 [15761491.001]
  • [Cites] J Neurooncol. 1995;24(1):21-8 [8523069.001]
  • [Cites] Cancer Res. 2005 May 15;65(10 ):4012-9 [15899790.001]
  • [Cites] Can J Neurol Sci. 1996 Nov;23(4):257-63 [8951203.001]
  • [Cites] Neuroradiology. 2000 May;42(5):363-7 [10872158.001]
  • [Cites] Pathol Int. 1999 Dec;49(12):1114-8 [10632935.001]
  • [Cites] Acta Neuropathol. 1992;83(4):445-8 [1575023.001]
  • [Cites] J Neurooncol. 2005 Sep;74(3):311-9 [16132523.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):337-42 [12142780.001]
  • [Cites] Med Pediatr Oncol. 1997 Mar;28(3):223-7 [9024522.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):23-8 [15779233.001]
  • [Cites] Mol Cell Biol. 2006 Apr;26(7):2661-74 [16537910.001]
  • [Cites] Neurochirurgie. 1999 Sep;45(3):237-42 [10567965.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):133-42 [14964309.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(1):81-5 [7679853.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Mod Pathol. 2006 May;19(5):717-25 [16528370.001]
  • [Cites] Acta Neurochir (Wien). 2004 Sep;146(9):1033-8; discussion 1038 [15340816.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):77-84 [15803379.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):644-50 [15105654.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1485-91 [15489652.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1038-43 [16406394.001]
  • [Cites] Hum Pathol. 2001 Feb;32(2):156-62 [11230702.001]
  • [Cites] Neuropathology. 2006 Feb;26(1):57-61 [16521480.001]
  • [Cites] J Clin Neurosci. 2003 May;10 (3):325-8 [12763338.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):74-9 [9892189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17745-50 [16301525.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1083-92 [9737241.001]
  • (PMID = 17377740.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA46274
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 Protein; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  • [Number-of-references] 34
  •  go-up   go-down


15. Knox MK, Ménard C, Mason WP: Leptomeningeal gliomatosis as the initial presentation of gliomatosis cerebri. J Neurooncol; 2010 Oct;100(1):145-9
Genetic Alliance. consumer health - Gliomatosis Cerebri.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For both entities, limited data exist to guide treatment and prognosis is poor.
  • We describe the case of a patient who presented with symptoms of increased intracranial pressure and diffuse leptomeningeal enhancement in the brain and spinal cord on MRI.
  • After a period of surveillance, intraparenchymal lesions developed in association with widespread diffuse infiltration.
  • The diagnosis of gliomatosis cerebri with diffuse leptomeningeal gliomatosis was established in hindsight.
  • Initial treatment consisted of six cycles of temozolomide chemotherapy.
  • [MeSH-major] Meningeal Neoplasms / complications. Meningioma / complications. Neoplasms, Neuroepithelial / etiology
  • [MeSH-minor] Adult. Brain / pathology. Female. Humans. Magnetic Resonance Imaging / methods. Spinal Cord / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1998 Oct;50(4):356-62; discussion 362 [9817460.001]
  • [Cites] J Neurooncol. 1999 Sep;44(2):163-8 [10619500.001]
  • [Cites] Neurosurgery. 1989 Oct;25(4):533-40 [2797391.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):201-5 [16200347.001]
  • [Cites] Neurology. 1992 Jan;42(1):252-4 [1310353.001]
  • [Cites] J Child Neurol. 1995 Jan;10(1):37-45 [7539465.001]
  • [Cites] Neurosurgery. 2003 Feb;52(2):324-29; discussion 330 [12535360.001]
  • [Cites] Radiographics. 2003 Jan-Feb;23(1):247-53 [12533659.001]
  • [Cites] Neurology. 2004 Jul 27;63(2):270-5 [15277619.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):209-16 [17031563.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):161-7 [9524095.001]
  • [Cites] Neurology. 2004 Jul 27;63(2):354-6 [15277636.001]
  • [Cites] Clin Neurol Neurosurg. 2000 Dec;102(4):223-226 [11154809.001]
  • [Cites] J Neurooncol. 1993 Mar;15(3):275-83 [8360714.001]
  • [Cites] Clin Neuropathol. 2009 Mar-Apr;28(2):73-82 [19353837.001]
  • [Cites] Acta Neurol Scand. 1989 Feb;79(2):133-9 [2711819.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1137-46 [12829152.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):45-9 [8455062.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):84-92 [8042560.001]
  • [Cites] J Clin Neurosci. 2006 Feb;13(2):298-301 [16431108.001]
  • [Cites] Neurosurgery. 1990 Oct;27(4):516-21; discussion 521-2 [2172859.001]
  • [Cites] Ann Neurol. 1980 Dec;8(6):605-8 [6260012.001]
  • (PMID = 20146082.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Heran NS, Yong RL, Heran MS, Yip S, Fairholm D: Primary intradural extraarachnoid hodgkin lymphoma of the cervical spine. Case report. J Neurosurg Spine; 2006 Jul;5(1):61-4
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On imaging studies the lesion mimicked the appearance of a meningioma.
  • The procedure was limited to biopsy sampling and the patient was treated further with adriamycin, bleomycin, vincristine, and dacarbazine chemotherapy, after which remission was demonstrated both clinically and on images.
  • Analysis of a frozen section obtained during the procedure aided in the diagnosis of the tumor, thus preventing further resection and the potential neurological complications associated with more radical resection.
  • [MeSH-major] Hodgkin Disease / pathology. Spinal Cord Neoplasms / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16850958.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Yamashita T, Sakaura H, Oshima K, Iwasaki M, Yoshikawa H: Solitary intradural extramedullary lymphoma of the cervical spine. J Neurosurg Spine; 2010 Apr;12(4):436-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lesion mimicked the appearance of meningioma on MR imaging.
  • Positron emission tomography showed increased accumulation of fluorine-18-labeled fluorodeoxyglucose only in the cervical lesion.
  • Based on histopathological findings, diffuse, large B-cell type non-Hodgkin lymphoma was diagnosed.
  • Postoperatively, the patient was treated with 2 courses of chemotherapy by intrathecal injection of methotrexate, cytarabine, and prednisolone and 4 courses of intravenous rituximab, an antibody binding to CD20 on the surface of B cells.
  • [MeSH-major] Cervical Vertebrae. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / surgery. Spinal Neoplasms / diagnosis. Spinal Neoplasms / surgery
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Chemotherapy, Adjuvant. Cytarabine / administration & dosage. Fluorodeoxyglucose F18. Humans. Injections, Intravenous. Injections, Spinal. Magnetic Resonance Imaging. Male. Methotrexate / administration & dosage. Middle Aged. Positron-Emission Tomography. Prednisolone / administration & dosage. Radiopharmaceuticals. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20367381.001).
  • [ISSN] 1547-5646
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Radiopharmaceuticals; 04079A1RDZ / Cytarabine; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 4F4X42SYQ6 / Rituximab; 9PHQ9Y1OLM / Prednisolone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


18. Kotil K, Bilge T, Olagac V: Primary intradural myxoid chondrosarcoma: a case report and review in the literature. J Neurooncol; 2005 Nov;75(2):169-72
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therapeutic experience with primary spinal mesenchymal chondrosarcomas is also extremely limited.
  • The exact origin of rare intradural spinal chondrosarcomas remains obscure.
  • Experience with primary spinal mesenchymal chondrosarcomas is also extremely limited.
  • CONCLUSION: The differential diagnosis considered in the present case included meningioma, plasmacytoma, and non-neoplastic intradural spinal cord lesion.
  • We emphasize the benefit of surgical resection without radiotherapy and/or chemotherapy.
  • This case presents the first case in the literature of an primary spinal intradural myxoid chondrosarcoma.
  • [MeSH-major] Chondrosarcoma, Mesenchymal / diagnosis. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / pathology. Pia Mater / pathology
  • [MeSH-minor] Adult. Dura Mater / surgery. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Radiography. Time Factors. Treatment Outcome. X-Rays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1977 Aug;40(2):818-31 [890662.001]
  • [Cites] J Neurosurg. 1994 May;80(5):928-30 [8169637.001]
  • [Cites] Surg Neurol. 1989 Jun;31(6):470-2 [2718090.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Feb;81(2):828-34 [8636311.001]
  • [Cites] Clin Orthop Relat Res. 1982 Jun;(166):226-32 [7083677.001]
  • [Cites] Neurosurgery. 2001 Feb;48(2):420-3 [11220388.001]
  • [Cites] Clin Orthop Relat Res. 1993 Sep;(294):90-5 [8358950.001]
  • [Cites] Spine (Phila Pa 1976). 1978 Sep;3(3):202-9 [715548.001]
  • [Cites] Clin Neuropathol. 1995 May-Jun;14(3):150-3 [7671456.001]
  • [Cites] Cancer. 1986 Jun 15;57(12 ):2444-53 [3697943.001]
  • (PMID = 16283441.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


19. Rushing EJ, Olsen C, Mena H, Rueda ME, Lee YS, Keating RF, Packer RJ, Santi M: Central nervous system meningiomas in the first two decades of life: a clinicopathological analysis of 87 patients. J Neurosurg; 2005 Dec;103(6 Suppl):489-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system meningiomas in the first two decades of life: a clinicopathological analysis of 87 patients.
  • OBJECT: The occurrence of meningiomas in children younger than 20 years of age is rare, accounting for less than 3% of all childhood tumors of the central nervous system.
  • The authors of this study sought to add to the limited available information regarding clinicopathological factors that influence outcome, disease progression, and survival in children with meningiomas.
  • METHODS: Eighty-seven cases of childhood meningiomas were identified and classified according to World Health Organization (WHO) 2000 criteria.
  • In addition to the WHO classification, the following potential prognostic factors were analyzed: age, sex, extent of resection, history of radiotherapy, diagnosis of neurofibromatosis Type 2 (NF2) or other inherited syndromes, and the presence of a comorbidity.
  • Tumor location was supratentorial in 64% of the patients, infratentorial in 16%, intraventricular in 12%, and spinal in 8%.
  • Histopathological analysis revealed 62 (71%) WHO Grade I, 21 (24%) Grade II, and four (5%) Grade III meningiomas.
  • One patient received adjuvant chemotherapy and four received radiotherapy.
  • CONCLUSIONS: Using survival data from this unique patient cohort, the authors found that recurrence-free survival time was significantly related to WHO grade (p = 0.002), but overall survival time was not significantly linked to any of the potential prognostic factors considered in this study (p = 0.06).
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / physiopathology. Meningioma / pathology. Meningioma / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16383246.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Smith ER, Ott M, Wain J, Louis DN, Chiocca EA: Massive growth of a meningioma into the brachial plexus and thoracic cavity after intraspinal and supraclavicular resection. Case report and review of the literature. J Neurosurg; 2002 Jan;96(1 Suppl):107-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive growth of a meningioma into the brachial plexus and thoracic cavity after intraspinal and supraclavicular resection. Case report and review of the literature.
  • Extracranial meningiomas comprise approximately 2% of all meningiomas.
  • Involvement of peripheral nerves by meningioma, either by a primary tumor or through secondary extension of an intraaxial lesion, is a much rarer entity; there have been only two reported primary brachial plexus meningiomas and one description of secondary involvement of the brachial plexus by extension of an intraaxial lesion.
  • Although thoracic cavity meningiomas have been described in the literature, their pathogenesis is poorly understood.
  • The authors present the case report of a 36-year-old man who was initially treated for a thoracic spinal meningioma that infiltrated the brachial plexus.
  • After resection, progressive and massive growth with infiltration of the brachial plexus and pleural cavity occurred over a 5-year period despite radio- and chemotherapy.
  • [MeSH-major] Brachial Plexus Neuropathies / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasm Recurrence, Local / surgery. Peripheral Nervous System Neoplasms / surgery. Thoracic Neoplasms / surgery
  • [MeSH-minor] Adult. Decompression, Surgical. Fatal Outcome. Follow-Up Studies. Humans. Laminectomy. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Reoperation. Thoracic Vertebrae / pathology. Thoracic Vertebrae / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brachial Plexus Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11795697.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Bauer JA, Frye G, Bahr A, Gieg J, Brofman P: Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs. Invest New Drugs; 2010 Oct;28(5):694-702
Hazardous Substances Data Bank. CYANOCOBALAMIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Given the limited options available to treat canine cancers, the use of companion animals for evaluating new drugs may identify better therapies for veterinary and human oncology.
  • (1) A 13 year-old female spayed Giant Schnauzer with inoperable thyroid carcinoma and hypercalcemia. (2) A 6 year-old male neutered Golden Retriever with a malignant peripheral nerve sheath tumor (MPNST). (3) A ten yr-old neutered male Bichon Frise with apocrine gland anal sac adenocarcinoma (AGACA). (4) A 7 year-old female spayed Labrador mix with spinal meningioma following partial surgical resection.
  • (1) The Giant Schnauzer demonstrated a 77% reduction in tumor volume after ten weeks of daily NO-Cbl treatment. (2) The Golden Retriever demonstrated a 53% reduction in tumor volume after 15 months of daily NO-Cbl therapy. (3) The Bichon Frise demonstrated a 43% regression of the primary tumor and a 90% regression of an iliac lymph node measured by MRI after 15 months of treatment.
  • After 61 months, the dog currently has stable disease, normal liver enzymes, CBC analysis, and no evidence of toxicity. (4) The Labrador demonstrated complete regression of the residual tumor after 6 months of treatment.
  • The use of NO-Cbl capitalizes on the tumor-specific properties of the vitamin B12 receptor and represents a promising anti-cancer therapy.
  • [MeSH-major] Dog Diseases / drug therapy. Neoplasms / veterinary. Nitroso Compounds / therapeutic use. Vitamin B 12 / analogs & derivatives
  • [MeSH-minor] Animals. Antineoplastic Agents / metabolism. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Dogs. Dose-Response Relationship, Drug. Female. Magnetic Resonance Imaging. Male. Tumor Burden. Ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Invest New Drugs. 2011 Oct;29(5):1122
  • [Cites] Eur J Cancer. 2004 Apr;40(6):858-80 [15120042.001]
  • [Cites] J Vet Intern Med. 1988 Jan-Mar;2(1):41-6 [3221354.001]
  • [Cites] Nat Med. 2005 Oct;11(10):1018 [16211022.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Jun;23(2):181-93 [15354401.001]
  • [Cites] J Am Vet Med Assoc. 1991 May 1;198(9):1618-21 [2061177.001]
  • [Cites] J Am Anim Hosp Assoc. 1998 Jan-Feb;34(1):19-25 [9527425.001]
  • [Cites] Vet Radiol Ultrasound. 2001 Sep-Oct;42(5):471-4 [11678572.001]
  • [Cites] J Small Anim Pract. 1999 May;40(5):206-10 [10385862.001]
  • [Cites] J Am Vet Med Assoc. 2006 Aug 15;229(4):542-8 [16910854.001]
  • [Cites] J Vet Intern Med. 2002 Jan-Feb;16(1):100-4 [11822797.001]
  • [Cites] Clin Tech Small Anim Pract. 2007 May;22(2):75-81 [17591293.001]
  • [Cites] Brief Funct Genomic Proteomic. 2005 Jul;4(2):112-28 [16102268.001]
  • [Cites] Anticancer Drugs. 1998 Mar;9(3):239-44 [9625434.001]
  • [Cites] J Nucl Med. 1997 May;38(5):717-23 [9170435.001]
  • [Cites] Semin Vet Med Surg (Small Anim). 1996 Nov;11(4):225-34 [9020576.001]
  • [Cites] Aust Vet J. 2005 Jun;83(6):340-3 [15986909.001]
  • [Cites] Cancer Invest. 2000;18(8):781-92 [11107448.001]
  • [Cites] Mayo Clin Proc. 2000 Jun;75(6):568-80 [10852417.001]
  • [Cites] J Am Vet Med Assoc. 1975 Mar 1;166(5):511-7 [1112759.001]
  • [Cites] Aust Vet J. 2005 Apr;83(4):208-14 [15907038.001]
  • [Cites] J Am Anim Hosp Assoc. 1998 Mar-Apr;34(2):109-12 [9507422.001]
  • [Cites] Vet Pathol. 2004 Jul;41(4):307-18 [15232130.001]
  • [Cites] J Am Anim Hosp Assoc. 1997 Jul-Aug;33(4):307-12 [9204465.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 3;94(13):1010-9 [12096086.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):420-30 [12189384.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39461-9 [12881518.001]
  • [Cites] J Am Vet Med Assoc. 1995 Apr 1;206(7):1007-9 [7768706.001]
  • [Cites] J Am Vet Med Assoc. 2003 Sep 15;223(6):825-31 [14507100.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] J Vet Intern Med. 1994 May-Jun;8(3):236-9 [8064663.001]
  • [Cites] J Am Anim Hosp Assoc. 1995 Jul-Aug;31(4):349-59 [7552669.001]
  • [Cites] In Vivo. 1994 Jan-Feb;8(1):133-43 [8054503.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(15):5588-94 [16847314.001]
  • [Cites] J Am Vet Med Assoc. 1989 Dec 1;195(11):1580-3 [2599941.001]
  • [Cites] Vet Comp Oncol. 2003 Jun;1(2):94-104 [19379321.001]
  • [Cites] J Neurosurg Anesthesiol. 1994 Apr;6(2):111-5 [8012169.001]
  • [Cites] J Small Anim Pract. 1981 Mar;22(3):119-28 [7230749.001]
  • [Cites] Vet Surg. 2006 Apr;35(3):267-70 [16635006.001]
  • [Cites] Vet Pathol. 1998 May;35(3):223-6 [9598587.001]
  • [Cites] PLoS One. 2007 Dec 12;2(12):e1313 [18074035.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Mar;25(1):97-105 [16761625.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 1;98(3):161-2 [16449674.001]
  • [Cites] J Am Vet Med Assoc. 1987 Sep 15;191(6):720-6 [3679964.001]
  • (PMID = 19557306.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA095020
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitroso Compounds; 0 / nitrosylcobalamin; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


22. Benesch M, Siegler N, Hoff Kv, Lassay L, Kropshofer G, Müller H, Sommer C, Rutkowski S, Fleischhack G, Urban C: Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study. Anticancer Drugs; 2009 Oct;20(9):794-9
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nineteen heavily pretreated patients (males, n = 14; females, n = 5; median age at diagnosis 8.5 years; range, 1.4-22 years) were given intrathecal liposomal cytarabine on a compassionate use basis for recurrent refractory medulloblastoma (n = 12), mixed germ cell tumor (n = 2), central nervous system primitive neuroectodermal tumors of the pons (n = 1), anaplastic ependymoma (n = 1), anaplastic oligodendroglioma (n = 1), atypical teratoid rhabdoid tumor (n = 1), or rhabdoid papillary meningioma (n = 1).
  • Duration of treatment ranged from (1/2) to 10 months.
  • Eleven patients (57.9%) did not show any side effects, whereas eight patients (42.1%) developed side effects related to either chemical arachnoiditis (n = 4) or neurological progression (n = 2).
  • Less typical treatment-related symptoms (e.g. lethargy, ataxia, and slurred speech) were observed in two patients.
  • Treatment with intrathecal liposomal cytarabine was discontinued twice because of side effects.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Brain Neoplasms / drug therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Compassionate Use Trials. Delayed-Action Preparations. Drug Resistance, Neoplasm. Female. Humans. Infant. Injections, Spinal. Liposomes / administration & dosage. Male. Retrospective Studies. Salvage Therapy. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617818.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Delayed-Action Preparations; 0 / Liposomes; 04079A1RDZ / Cytarabine
  •  go-up   go-down






Advertisement